



Index

A

Abciximab, 135
 Abelcet, 97
 Accountable care organizations, 2
 AccuFlow, 123
 Accuflux, 123
 Acetazolamide, 97
 Acetylcysteine, 94, 97
 Acyclovir, 97
 Adverse drug events, 2, 4, 75, 79–80
 Agency for Healthcare Research and Quality, 2, 12
 Alaris System, 61
 Alarm(s), 23–24
 Call-back, 54
 volume, 89
 Albumin, 94, 97
 Alert(s), 52, 53
 dosing, 93
 fatigue, 51
 special, 101
 Alprostadil, 91, 94
 AmBisome, 97
 Ambulatory infusion pump, 119,
 120–122, 125–126
 limitations of, 122–123
 special features, 122
 Amikacin, 97
 Aminocaproic acid, 91, 94, 99, 100
 Aminophylline, 91, 94, 97, 99, 100
 Amiodarone, 65, 91, 94, 99, 100
 Amphotericin B, 64, 97
 Ampicillin, 97
 Ampicillin/sulbactam, 97
 Anesthesia Patient Safety Founda-
 tion, 83
 Antibiotics, 60, 94, 121
 Anticoagulants, 54
 Antiinfectives, 119, 123, 125
 Antimicrobials, 63–64
 Antithrombin III, 91, 97
 Argatroban, 91
 ASHP, 193, 194

Assessment, go-live, 136
 Asset tracker report, 175
 Automated dispensing cabinets, 143
 Automated mandatory bolus (AMB),
 105
 Automated reports, 174
 Azathioprine, 97

B

B Braun Outlook, 61
 Background infusion, 73
 Barcode scanning, 2, 90, 139,
 141–142, 171, 194
 Basal rate, 73
 Basic delivery, 67
 Bedside
 barcoding, 2
 workstations, 194
 Beyer, John P., 193–198
 Beyond-use date, 139, 140
 Bidirectional interface, 193
 Biomedical services, 183
 checklist, 184
 Blood products, 64
 Bolus dose, 59, 65–66, 73
 breakthrough, 81
 followed by continuous infusion, 54
 option, 93
 Bolus infusion programming units,
 101–102
 Borchart, Michelle L., 11–27, 59–71,
 113–118, 183–191
 Breland, Burnis D., 129–137, 173–182
 Brownlee, Michael J., 193–198
 Bumetanide, 91, 94, 97, 99, 100
 Bupivacaine, 106, 107, 108, 109, 111

C

CADD-Solis VIP, 120
 Caffeine citrate, 97
 Calcium chloride, 91, 94, 97, 99, 100
 Calcium gluconate, 91, 94, 97, 99, 100

Call-back alarm, 54
 Capital letters, 75
 Carlson, Melissa K., 87–103
 Caspofungin, 97
 Cause, 153, 155, 156, 157, 158
 Cefazolin, 97
 Cefepime, 97
 Cefotaxime, 97
 Cefoxitin, 97
 Ceftazidime, 97
 Ceftriaxone, 97
 Cefuroxime, 97
 Centers for Medicare & Medicaid Services, 83
 Change implementation, 145–151
 Character limits, 75
 Chard, Amy K., 119–127
 Checklists, 146, 148, 169
 Chemotherapy agents, 61, 67, 119, 121, 123
 Chloramphenicol, 97
 Chloroprocaine, 106, 112
 Chlorothiazide, 97
 Ciprofloxacin, 97
 Cisatracurium, 91, 94, 99, 100
 reference card, 93
 Class times, space, 132
 Clindamycin, 97
 Clinical advisories, 113, 115
 Clinical care area, 87
 monitoring quality in, 173, 175
 oncology and, 113, 114–115
 smart pump implementation and, 59, 64, 65
 Clinical notes, 68
 Clinical practice, 76
 Clinical scenarios, 197
 Clinician compliance, 129
 Clinidine, 107
 Clonidine, 107
 Compliance, 178
 reports, 195
 Compounded sterile products, 139–142

Compounding, 139–144
 Concentration
 of CSPs, 141
 of oncology infusions, 115–116
 pediatric standard, 90, 91–92
 Container-closure systems, 140
 Continuous epidural infusion, 105, 107
 adult drug library, 108
 Continuous infusion, 73, 121
 adult epidural drug library for, 108
 of opioids, 81–82
 pediatric standard concentrations for, 91–92
 Continuous medication dose limits, 62
 Continuous quality improvement, 174
 Critical criteria, 11, 14
 Cyclosporine, 91, 94

D

Dantrolene, 91
 Data
 logs, 4, 6
 management of, 197–198
 sharing, 177
 Dataset, 145
 modifications, 147–148
 Delay infusion/delayed run feature, 67
 Delivery
 at end of infusion, 67
 limit method, 105
 methods, 66–67
 mode, 73
 Demand dose, 73, 81, 105
 lockout, 105, 122
 Desmopressin, 97
 Detection, 153
 score, 157
 Dexamethasone, 97
 Dexmedetomidine, 91, 94, 99, 100, 180
 Digoxin, 97
 Diltiazem, 91, 94, 97, 99, 100
 Diphenhydramine, 97, 123

- Display name, 60–61
- Dobutamine, 91, 95
- Dopamine, 60–61, 91, 95
- Dose
 - parameters for, 73
 - range settings for, 53
 - rate units for, 59
 - stacking of, 82
- Dose error reduction system (DERS),
 - 1, 3
 - epidural and, 106
 - monitoring quality, pump use, 173
 - patient-controlled analgesia and, 74, 79
 - pump implementation and, 53–54
- Dose limit, 73
 - alternative opioid medications and, 80
 - continuous medication and, 62
 - epidural, 109–110
 - opioid-naïve pediatric patients and, 78
 - volume-based, 109–110
- Dosi-Fuser, 123, 124
- Dosing
 - alerts, 93
 - limits, 100–101
 - pediatric limits, continuous infusion, 94–96
 - pediatric units, 92
 - rate units, 62–63
- Doxycycline, 97
- Drug administration, epidural, 107
- Drug concentration, 79–80
 - epidural drug delivery, 108
- Drug library, 145
 - additions, modifications checklist for, 170–171
 - approval process for, 169
 - bolus and loading doses for, 65–66
 - building, 59–71
 - clinical notes and, 68
 - continuous medication dose limits in, 62–63
 - delivery at infusion end and, 67
 - delivery methods in, 66–67
 - development of, 194–195
 - division of, 64–65
 - epidural delivery and, 107
 - epidural, intrathecal, 105–112
 - future state of, 169, 171
 - go-live for, 129
 - medication concentration in, 61
 - medication name and display name in, 60–61
 - multiple pump types and, 101
 - nursing collaboration and, 68
 - oncology, 113–118
 - patient-controlled analgesia and, 73–86
 - pediatric, 87–103
 - pump implementation and, 52–53
 - pump validation and, 102, 167
 - push, 59, 183
 - review of limits for, 68–69
 - special considerations and, 63–64
 - stand-by or delayed run option for, 67
 - use of, 53
 - validation of, 168
 - validation procedures for, 169
 - vendor support for, 68
- Drug library subset, 51, 64, 87
 - for epidural drug delivery, 109
 - examples of, 65
 - for oncology, 114
 - pediatric medication lists for, 90–91
 - for pediatrics, 88–91
- Drug library updates, 145–151
 - checklists for, 183–191
 - flow chart for, 190
- Drug nomenclature, epidural drug delivery, 107
- Drug Quality and Security Act, 139
- Drug selection, epidural drug delivery, 106–17

E

Eckel, Stephen F., 105–112, 167–172
 ECRI Institute, 7, 12
 Edit variance report, 175
 Education
 of group, 131
 plan, 130–132
 process promotion, 132
 team, 130–131
 materials for, 132, 133
 Effect, 153
 Elastomeric pump, 119, 123–124, 126
 benefits of, 124
 limitations of, 124–125
 Electrolyte replacement, 123
 Electrolyte solutions, 119
 Electronic health record, 193–194
 Electronic medical record, 167, 169, 171
 Electronic medication administration record (eMAR), 171
 E-mail messages, 132
 Enable stand-by feature, 67
 Enalaprilat, 97
 Entity, 183
 Enzyme replacement, 119
 Epidural drug delivery
 administration and, 107
 dosing recommendations for, 109–110
 drug library subsets for, 109
 principles of, 106–107
 volume-based dose limits for, 109
 Epidural drug library, 105–112
 neonatal, 112
 obstetrics epidural, 111
 PCEA, 111
 Epinephrine, 91, 95
 Epoetin alfa, 97
 Ergonomics, 16
 Erythromycin lactobionate, 98
 Esmolol, 91, 95, 99, 100
 Evaluation, go-live, 136

F

Failure mode, 153, 157
 scoring for, 157, 158
 Failure mode and effects analysis (FMEA), 11, 120, 34, 153–154
 details for, 45–50
 drug library and, 35–36
 example of, 36
 information design and, 35
 medication limits information and, 36
 participants and, 34–35
 pump example of, 161–165
 pump programming and, 35
 scripted scenarios for, 35
 Fentanyl
 epidural drug library and, 106, 108, 109
 patient-controlled analgesia and, 78, 79, 81, 82, 83
 pediatric drug library and, 91, 98
 Fentanyl + bupivacaine, 108, 111
 Fentanyl + bupivacaine + clonidine, 108
 Filgrastim, 98, 123, 125
 510(k) clearance, 1, 7
 Flowsheets, 194
 Fluconazole, 98
 Food and Drug Administration, 139, 141, 146
 infusion pump risk reduction, guidance from, 7
 smart pumps and, 6–7, 87
 Fosarnet, 98
 Fosphenytoin, 95, 98
 FREEDOM60, 125
 FreedomEdge, 125
 Function, 153
 Functionality, 197
 Furosemide, 91, 98

G

-
- Ganciclovir, 98
 - Gentamicin, 98
 - Ghafoor, Virginia L., 73–86, 153–165
 - Glycopyrrolate, 98
 - Go-live, 129
 - biomedical services checklist for, 184
 - checklists for, 183–191
 - considerations for, 183–184
 - day, 135–136
 - education, 129–137
 - implementation team checklist for, 184
 - information technology checklist for, 186
 - nursing/nurse educators checklist for, 185
 - pharmacy services checklist for, 186
 - preparations for, 134–135
 - sterile services checklist for, 184
 - supply chain/inventory specialist checklist for, 185
 - Granisetron, 98
 - Green, Kathleen G., 113–118
 - Guiding principles, 56
 - need for, 51–52
 - sample of, 52

H

-
- Hard dose limit, 173
 - case study for, 181
 - Harder, Kathleen, 29–50
 - “Health Care at the Crossroads,” 2
 - Healthcare FMEA plan, 153, 154–155
 - mitigation strategy for, 158
 - multidisciplinary team for, 155–165
 - process mapping for, 156–157
 - project selection criteria for, 155
 - risk assessment and, 157
 - scope of, 155
 - Hematopoietic stem cell transplant, 114

- Heparin
 - drug library building and, 60, 65
 - in pediatric drug library, 91, 95, 99, 100
 - pump implementation and, 54
- High-alert/high-risk medications, 54–55, 60, 62, 77, 105
- High-concentration/high-dose patients, 76
- High-concentration narcotic infusions, 55
- Home infusion pumps, 119–127
- Hospira
 - GemStar Blue, 120
 - Plum, 61
- Human factors, 29, 30, 34, 36, 120
- Hydralazine, 98
- Hydration, 119, 121, 123
- Hydrocortisone, 98
- Hydromorphone
 - epidurals and, 106, 107, 108, 109
 - patient-controlled analgesia and, 75, 76, 78, 79, 80, 81, 82, 83
 - pediatrics and, 91
- Hydromorphone + bupivacaine, 108

I

-
- I Flow Homepump Eclipse and C-series, 123
 - Imipenem/cilastatin, 98
 - Immune globulin, 95
 - Incremental dose, 73
 - Indomethacin, 98
 - Information technology checklist, 186
 - Infusion limits in oncology, 116
 - Infusion pump, 1, 6–7
 - alarms and indicators for, 23–24
 - basic operation and programming of, 21–23
 - desirable features of, 21–27
 - dose error reduction system/
 - electronic interface for, 25–26
 - education, service, vendor support for, 27

general requirements for, 21
 information for, 27
 libraries management for, 168
 miscellaneous requirements for,
 26–27
 power source/battery for, 26
 Infusion status report, 175
 Infusion summary report, 175
 “Initiative to Reduce Infusion Pump
 Risks,” 7
 Inotropes, 119, 121
 Institute for Safe Medication Practices
 (ISMP) 3, 79–80
 compounding, packaging and, 139
 drug library updating and, 146
 drug library validation and, 169
 epidurals and, 106
 healthcare FMEA and, 154
 standard PCA order sets and, 75
 standardized concentrations and,
 115–116
 Institute of Healthcare Improvement
 Triple Aim, 119
 Institute of Medicine, 2
 Insulin, 54, 60, 88, 91
 Integration
 preparing for, 194–196
 workflow of, 196
 Intensive care patients, 76
 Interdisciplinary team, 167–168
 Intermittent infusion therapy, 66, 67,
 121
 Interoperability, 193
 Intrathecal drug library, 105–112
 Intravenous (IV) fluids, 61, 64, 95, 99,
 100
 Intravenous (IV) solution changes,
 14–15
 Inventory specialist checklist, 185
 Iron, 123, 125
 Isoproterenol, 91, 95
 Item, 153

J

Joint Commission, 2, 61, 83, 139
 practice risk assessment and, 154
 safe opioid use and, 74

K

K cocktail
 adult, 95
 pediatric, 95
 K/Na phosphorous replacement, 95
 Ketamine, 76, 79, 91, 95
 Ketorolac, 98
 KLAS, 12
 Kleppin, Susan M., 145–151
 KVO (keep vein open), 67

L

Labeling, 141–142
 of infusion lines, 54
 Labetalol, 91, 95, 98, 99, 100
 Laminated cards, 134–135
 Large-volume pump, 87, 88, 89
 high-concentration narcotic
 infusions and, 55
 non-weight-based bolus dosing
 limits and, 99–100
 oncology drug library and, 117
 quality case studies for, 180
 Latin square, 31, 32
 Leadership
 structure, 168
 support, 132
 Leucovorin, 98
 Levocarnitine, 98
 Levofloxacin, 98
 Levorphanol, 81
 Levothyroxine, 98
 Lidocaine, 91, 95, 99, 100
 Line labels, 51
 Linezolid, 98
 Loading dose, 65–66, 73
 for patient-controlled analgesia,
 80–81

Local anesthetics, 106
 Lockout, 74
 interval, 81, 82–83
 Look-alike medications, 75, 143
 Lorazepam, 91, 95
 Lower hard dose limit, 3
 drug library building and, 59, 62–63
 for oncology, 113, 116
 of patient-controlled analgesia, 73, 81
 Lower soft dose limit, 3
 drug library building and, 59, 62–63
 for oncology, 113, 116
 of patient-controlled analgesia, 73, 81

M

Magnesium sulfate, 95, 98
 Manual transfer, 148–149
 Manufacturer support, 149–150
 Manufacturer and User Facility
 Device Experience (MAUDE), 1, 3, 6–7, 16, 74
 Medfusion 2001, 125
 Medfusion 3500 Syringe Pump with
 PharmGuard, 125
 Medication administration, 53
 Medication concentration, 55, 61
 variable, 61
 Medication errors, 2, 4–5
 Medication limits, 60
 information, 36
 Medication list, 60
 for oncology, 114–115
 for pediatrics, 90–91
 Medication name, 60–61
 Medication pump programming, 52
 Medication tables, 63
 Medications
 infused by clinical care area report, 175
 PCA concentrations of, 56
 MedMarx, 2, 74

Meperidine, 76, 77
 Meperidine HCl, 109
 Meropenem, 98
 Methadone, 76, 79, 80, 81, 98
 Methylprednisolone, 98
 Metoclopramide, 98
 Metronidazole, 98
 Midazolam, 91, 95, 98
 Milrinone, 91, 95, 99, 100
 Minibags, 115
 Minimum effective analgesic concentration, 73
 Mitigation strategy, 158
 Mode of administration, 73
 Monitoring, go-live day, 136
 Moog/Curlin 6000 CMS, 120
 Morphine
 in patient-controlled analgesia, 75, 76, 78, 79, 80, 81, 82, 83
 in epidurals, 106, 108, 109
 in pediatrics, 98
 Morphine + bupivacaine, 111
 Morphine sulfate, 109
 Multidisciplinary team, 145–146, 150, 155–156
 Multistep therapy, 66–67
 Mycophenolate, 95, 98

N

Nafcillin, 98
 Nalbuphine, 76, 79, 80
 Naloxone, 62, 91, 95
 National Coordinating Council for
 Medication Error Reporting and
 Prevention index, 74
 National Drug Code, 139, 141
 National Patient Safety Goals
 (2003), 61
 (2006), 1
 Neonatal patient, 87, 88–89
 epidural drug library and, 112
 Nesiritide, 91, 95, 99, 100
 Nesting, 59, 61

New technology adoption, 149
 Newsletters, 132
 Nicardipine, 91, 95–96
 Nitroglycerin, 91, 96
 Nitroprusside, 91, 96
 Nonstandard analgesics patients, 76
 Norepinephrine, 92, 96
 Nurse-activated dosing, 73
 Nursing, 30
 checklist, 185
 collaboration, 68
 practice, 77

O

Obstetric epidural drug library, 112
 Octreotide, 92, 96, 98, 99, 100
 Oncology drug library, 113–118
 large-volume pump and, 117
 Ondansetron, 92, 96, 98
 Opiates, 54
 Opioid-naïve patient, 76, 81
 patient-controlled analgesia dose
 limits for, 82
 pediatric patients, 78
 Opioid-tolerant patients, 76, 81
 dose limits for, 83
 Opioids, 76–77, 106, 119
 Order sets, 75, 147
 Outsourcing facility, 139–140, 143
 Overfill volume, 116, 141
 Override, 173, 175–177, 180
 variance details report, 175

P

Packaging
 compounded sterile products,
 142–143
 medication, 139–144
 PACU, 77
 Pantoprazole, 92, 96, 98
 Parenteral nutrition, 119
 Password protection, 51, 54

Patient weight changes, 102
 Patient-controlled analgesia, 74,
 121–122
 clinical practice integration for,
 75–76
 concentration of, 79–80
 continuous infusion of, 81–82
 dose limits for adult opioid-naïve
 patients, 82
 dose parameters for, 76–77
 dosing, 73, 81
 drug library starting point for, 75
 drug selection for, 76–79
 future technology and, 83–84
 loading dose for, 80–81
 policies examples for, 77
 principles for, 55–56
 starting dose parameters for, 82
 time limits for, 82–83
 Patient-controlled epidural analgesia,
 105, 107, 109, 110, 111
 Pediatrics
 bolus dose option for, 93–94
 drug library for, 87–103
 large-volume pump dosing limits
 for, 94–96
 medication lists for, 90–91
 standard concentrations for, 90, 91
 Pentobarbital, 92, 96
 Periodic automatic replenishment, 183
 Personalities, 64, 87
 Pharmacy services checklist, 186
 Phelps, Pamela K., 1–10, 11–27,
 51–57, 59–71, 183–191
 Phenobarbital, 98
 Phenylephrine, 92, 96
 Phytonadione, 98
 Piggyback dose/infusion, 60, 66, 67
 Piperacillin, 98
 Piperacillin/tazobactam, 98
 Potassium chloride, 96, 99
 Practice
 change, 102
 opportunities, 133

Primary, no secondary delivery, 66
 Primary, secondary allowed delivery, 66
 Primary or secondary delivery, 66
 Private sessions, 177
 Probability, 153
 score, 157
 Procainamide, 92, 96
*Proceedings from the ISMP Summit on
 the Use of Smart Infusion Pumps*, 168
 Prochlorperazine, 99
 Product testing, 140
 Profiles, 64, 87
 Programmed intermittent epidural
 bolus (PIEB), 105, 107, 110
 Promethazine, 99
 Propofol, 92, 96, 99, 100
 Propranolol, 99
 Pump edits, 173, 180
 Pump
 implementation procedures, 51–57
 ownership, responsibility, 174
 process standardization, 52
 programming, 35
 removal, 136
 rental process, 15–16
 standardization for efficiency and
 safety, 52
 updates, 53
 utilization, 173–182

Q

Quality
 monitoring, 173–182
 reports, 175–176
 Quinn, Melissa M., 153–165
 Quinupristin/dalfopristin, 99

R

Ramp up option, 66
 Ranitidine, 92, 96, 99
 Refresher training, 131
 Reports, 175–176

framework, 177
 manager, 176
 use of, 178
 Request for proposal (RFP), 11, 12–13
 sample of, 18–20
 Respiratory monitoring, 83–84
 Results posting, 177
 Return on investment (ROI), 1, 5–6
 Rifampin, 99
 Risk assessment, 157
 Risk priority number, 153, 157–158
 Ropivacaine, 106

S

Safety precautions, 134–135
 Safety software, 173, 174–177,
 180–181
 use case study, 180
 Schedule II medications, 55
 Score cards, 12
 Scrolling, 51
 Secondary delivery only, 66
 Secondary infusion, 60, 66
 Sedatives, 54
 Severity, 153
 score, 157
 Shift-specific reports case study, 181
 Sigma Spectrum, 61
 Signs, 132
 Simonson, Dana A., 119–127
 Simulation training, 197
 Skoglund, Angela K., 87–103
 Smart infusion pumps, 87
 assessment of, 12, 14
 attributes of, 6
 examples of, 8
 high-risk medications and, 54–55
 implementation of, 196
 integration of, 193–198
 justification for, 1–10
 requirements for, 24–25
 selection of, 11–27
 selection assessment points for, 15

Sodium bicarbonate, 92, 96, 99
 Sodium chloride, 94
 Soft dose limit, 173
 Software upgrade, 149
 Sound-alike medications, 75
 Specialty infusions, 119
 Standardization, CSPs, 141
 Stanek, Joseph B., 139–144
 Step-wise infusion, 114
 Sterile services, 183
 checklist, 183
 Stivers, Andrew P., 105–112, 167–172
 Storage, CSPs, 142–143
 Subcutaneous immunoglobulin, 125
 Sub-library groups, 89
 Success, 134
 Sufentanil, 106, 109
 Superusers, 129, 131–132
 Supplier support, 149–150
 Supply chain, 183
 checklist, 185
 Syringe pump, 87, 88, 119, 125
 weight-based dosing for intermittent infusions and, 97–99
 System, 183
 System FMEA model, 153
 steps in, 156

T

T34 syringe pump, 125
 Tacrolimus, 92, 96
 Tall-man lettering, 60, 75, 90
 Taper option, 66
 Team
 assignment, quality, 175
 development, 11
 meetings, 177
 Testing, 196
 Theophylline, 92, 96, 99, 100
 Thymoglobulin, 96
 Ticarcillin/clavulanate, 99
 Time interval, 74
 Timeline, education plan, 131

TMP/sulfamethoxazole, 99
 “To Err Is Human,” 2
 Tobramycin, 99
 Total parenteral nutrition, 61, 66, 96
 settings, 121
 Training, 196
 module, 133
 Tromethamine, 99

U

U.S. Pharmacopeia Convention
 Chapter <797>, 140
 Ump defects, 74
 Upper dose limits, 81
 Upper hard dose limit, 3
 drug library building and, 60, 62–63
 drug library development and, 74, 81
 in oncology, 113, 116
 Upper soft dose limit, 3
 drug library building and, 60, 62–63
 drug library development and, 74
 in oncology, 113, 116
 Usability testing, 11, 37
 candidate pump evaluation and, 30
 counterbalancing order of, 31–32
 instituting, 30–31
 Latin square in, 31, 32
 observer questions for, 41–44
 observers for, 33–34
 participant instructions for, 31
 participant questions for, 38–40
 process for, 32–33
 results of, 34
 scripted scenarios for, 33
 set-up for, 31
 User selection error, 61

V

Validation, accuracy, functionality,
 167–172
 Value analysis, 11, 13
 Valproate, 99

Vancomycin, 64, 96, 99
Variance detail report, 179
Vasopressin, 92, 96
Vasopressors, 62
Vecuronium, 92, 96
Vendor
 assessment, 12–13
 evaluation online resources, 7–8
 selection process, 12–14
 support, 68
Veterans Administration National
 Center for Patient Safety, 154
Vinblastine, 115
Vinca alkaloid agents, 115
Vincristine, 115
Vinorelbine, 115
Voriconazole, 99
VTBI (volume to be infused), 67

W

Weight-based dosing, 76, 78, 88
 limits, 92
Weighted decision matrix, 11, 14
Wireless applications, 16
Wireless communication transfer, 148
Wireless connectivity, 194
Wireless information transfer, 3
Wireless pump updates
 considerations for, 186–187
 flow chart for, 188–189
Wireless technology, 146–147
Workflows, 196–197

Z

Zidovudine, 99

